This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
SIG Corner
SIG Corner - Neuroprotection
Neuroprotection

Publishing date: June 2019


Chair: Francesca Cordeiro
Co-chair: Miriam Kolko

1. Goals of the SIG

SIG neuroprotection forms the basis of symposia, “tip of the month”, and puts neuroprotection on the map of important issues in glaucoma.

2. Provide a relevant breakthrough in the field

Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.
Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW.
Science. 2017 Feb 17;355(6326):756-760.

The paper was selected due to the promising results on nicotinamide as a potential neuroprotective drug to prevent retinal ganglion cell loss in glaucoma.

Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury.
Agostinone J, Alarcon-Martinez L, Gamlin C, Yu WQ, Wong ROL, Di Polo A.
Brain. 2018 Jul 1;141(7):1963-1980.

The paper was selected due to the shown effect of insulin on dendrite and synapse regeneration which may pave the way for regenerative treatments in glaucoma.

The search for EGS goal of “Paving the Way to Better Glaucoma Care” continues together with Outcome and other EGS Committees as well as SIGs, i.e. how to promote the best possible well-being and minimal glaucoma-induced visual disability in individuals with glaucoma within affordable healthcare systems.

The views expressed are those of the author(s) and are not necessarily those of the EGS.

SIG Corner editor: João Barbosa Breda


back to top